Stanford-LPCH Vaccine Program
Historically, vaccines against infectious agents have had a more profound impact on the health of the world's population than any other advance in the biomedical sciences. Vaccine research is entering an exciting phase of expansion and innovation which is expected to yield many new approaches to disease prevention and therapy that will be useful well beyond the traditional domain of infectious diseases. For example, novel strategies using vaccines to prevent or treat cancer and allergic diseases are now being developed. New models and techniques are now available to measure the benefit and cost of vaccination in different populations. The goal of the Stanford-LPCH Vaccine Program is to ensure that our faculty has the best possible opportunity to make important contributions to progress in this field and to bring the fruits of this research to people.
The Stanford-LPCH Vaccine Program was established in 1997 with Drs. Ann Arvin and Harry Greenberg as Directors. Ann Arvin, M.D. is Professor of Pediatrics and a Director of the Stanford-LPCH Vaccine Program. Dr. Greenberg is a Professor of Medicine, Senior Associate Dean - Research and Director of the Stanford-LPCH Vaccine Program. In 1999, Dr. Cornelia Dekker was appointed as the Medical Director for the Stanford-LPCH Vaccine Program to organize the clinical aspects of the program. In this regard, the Stanford-LPCH Vaccine Program has established the infrastructure to do clinical studies of vaccines in both children and adults. Collaborations with local medical groups, Vaden Student Health, and community child care centers encouraged enrollment into various clinical trials sponsored by NIH, the CDC and the pharmaceutical industry.
For more information on our vaccine program and current clinical trials, please go to the Stanford-LPCH Vaccine Program website at: (http://vaccines.stanford.edu/index.html).